AlloCure Inc.
This article was originally published in Start Up
Executive Summary
There are precious few options for addressing acute kidney injury, a condition that is characterized by a rapid deterioration of kidney function, often occurring in people with certain risk factors and co-morbidities. Some 300,000 to 500,000 people each year in the US suffer from AKI. AlloCure Inc. is developing bone marrow-derived adult stem cells harvested from anonymous donors, and prepared as an off-the-shelf therapy, to prevent and perhaps eventually treat AKI.
You may also be interested in...
Start-Up Previews (09/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target Cancer Metabolism," features profiles of Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals. Plus these Start-Ups Across Health Care: AlloCure, ArisGen, HistoSonics and NeuraviBiotechnology.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.